Kit for quantitative determination of neutrophil apolipoprotein in human serum and application thereof
By preparing and chemically cross-linking latex particles containing neutrophil apolipoprotein monoclonal antibodies, and combining them with a fully automated biochemical analyzer, the complexity of neutrophil apolipoprotein quantification in existing technologies has been solved, achieving rapid and accurate detection results.
Patent Information
- Application Number
- CN202411293230.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-14
- Publication Date
- 2024-11-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing technologies lack kits and detection methods for the quantitative determination of neutrophil apolipoproteins in human serum using latex-enhanced immunoturbidimetry, and traditional methods are complex to operate and difficult to automate.
A kit for latex-enhanced immunoturbidimetry is provided. By preparing a monoclonal antibody that specifically recognizes neutrophil apolipoproteins and chemically cross-linking it onto the surface of latex particles, the kit is combined with a fully automated biochemical analyzer for detection, achieving rapid and accurate quantitative determination.
It enables rapid and accurate detection of neutrophil apolipoproteins, with a detection sensitivity that is more than 10 times higher, good stability and repeatability, and is suitable for bacterial infection diagnosis and antibiotic efficacy monitoring.
Smart Images

Figure CN118897091A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biological detection, in particular to a kit for quantitatively determining neutrophil apolipoprotein in human serum and its application. Background Art
[0002] Human neutrophil lipocalin (HNL) is the main component of neutrophil secondary granules. When human peripheral blood neutrophils are stimulated and activated, HNL can be released from the cell to the outside of the cell. Studies have shown that when acute bacterial infection occurs, the content of neutrophil apolipoprotein in serum is positively correlated with the severity of the infectious disease; while in viral infection, the HNL content does not increase or increases slightly. By detecting its content in serum, it can reflect whether there is bacterial infection and the degree of bacterial infection. However, the currently commonly used enzyme-linked immunosorbent assay for detecting human serum neutrophil apolipoprotein has the disadvantages of complex operation and difficulty in automation.
[0003] When light passes through a turbid medium solution, due to the presence of turbid particles in the solution, part of the light is absorbed, and the amount absorbed is proportional to the amount of turbid particles. This method of measuring the amount of light absorption is called transmission turbidimetry. This method was reported by Schultre and Schuick in 1959 and was applied to the formation of complexes after the combination of plasma proteins and their antibodies, resulting in changes in turbidity, and then the transmission turbidimetry was performed. Generally, the transmission turbidimetry method for quantitative antibody-antigen is called immunoturbidimetry. However, in the classic immunoturbidimetry, a small amount of small antigen-antibody complexes is extremely difficult to form turbidity unless they are left for a long time: if a larger complex is formed, the amount of antigen and antibody used is also large, which obviously does not meet the requirements of microquantification. Therefore, the latex-enhanced immunoturbidimetry method, which is now widely used in biochemical analyzers, was developed. Its principle is to use the specific binding of antigens and antibodies to form complexes, and to quantify antigens or antibodies by measuring the amount of complex formation.
[0004] Latex-enhanced turbidimetric immunoassay is a homogeneous transmission turbidimetric immunoassay for body fluid protein detection. The principle is to cross-link monoclonal or polyclonal antibodies on the surface of nano-scale polymer latex microspheres. When the microspheres cross-linked with antibodies bind to the antigen, they will quickly aggregate together in a short period of time, changing the light transmittance of the reaction solution. The change in the light transmittance (i.e., absorbance) of the reaction solution has a strong correlation with the concentration of the antigen being tested, and can reflect the concentration of the antigen being tested within a certain range.
[0005] In the prior art, there is no related kit and detection method for determining the content of neutrophil apolipoprotein in human serum by latex enhanced immunoturbidimetry. Summary of the invention
[0006] The technical problem to be solved by the present invention is as described in the background technology, to provide a kit for quantitatively determining neutrophil apolipoprotein in human serum by latex enhanced immunoturbidimetry and its application.
[0007] In order to solve the above problems, the present invention proposes the following technical solutions:
[0008] One aspect of the present invention is to provide monoclonal antibodies against neutrophil apolipoprotein that can be used for latex enhanced immunoturbidimetry detection.
[0009] In a specific embodiment, the monoclonal antibody is combined with the Uniprot database to analyze the antigenicity, hydrophilicity and surface structure possibility of the protein sequence of neutrophil apolipoprotein (P80188, sequence SEQ NO.1), and selects a peptide of about 18 amino acids with high antigenicity, strong hydrophilicity and high surface possibility as an immune peptide: STSDLIPAPPLSKVPLQQC (named HNL-1-AG, sequence SEQ NO.2), the sequence corresponds to the amino acids 24-40 of the protein, and the terminal cysteine is artificially added to provide free thiol groups for coupling with carrier proteins. Nanjing GenScript Biotechnology Co., Ltd. is commissioned to synthesize and couple the immune peptide, provide a complete quality inspection report, and compare it with the nucleic acid database to determine its specificity.
[0010] In a specific embodiment, the antibody preparation process is as follows:
[0011] (1) Antigen preparation,
[0012] (2) Animal immunization BALB / C mice were immunized.
[0013] (3) Cell fusion,
[0014] (4) Monoclonal antibody screening,
[0015] (5) Preparation of monoclonal antibodies.
[0016] It can be understood that the above-mentioned method of producing neutrophil apolipoprotein-specific monoclonal antibodies using immune animals is mainly through the following protein expression systems, including: prokaryotic cell expression system, yeast expression system, insect cell expression system and mammalian cell expression system. The more advanced the expression system, the more comprehensive and complex the post-translational modification that can be completed, and the closer the recombinant protein expressed is to the natural protein in the human blood circulation.
[0017] Another aspect of the present invention is to provide a kit for quantitatively determining neutrophil apolipoprotein in human serum, the kit comprising latex particles coated with anti-human neutrophil apolipoprotein antibodies.
[0018] In a specific embodiment, the anti-human neutrophil apolipoprotein antibody is a monoclonal antibody that specifically recognizes an antigenic epitope of human neutrophil apolipoprotein, and the amino acid sequence of the antigenic epitope is shown in SEQ NO.1: STSDLIPAPPLSKVPLQQC.
[0019] In a specific embodiment, the latex particles are dissolved in solution 2, and the solution 2 also includes electrolytes, stabilizers, surfactants, preservatives, and buffer solutions.
[0020] In a specific embodiment, it also includes solution 1 and a quality control product, wherein solution 1 includes electrolytes, stabilizers, surfactants, preservatives and buffer; and the quality control product includes neutrophil apolipoprotein and a stabilizer.
[0021] In a specific embodiment, the method for preparing the latex particles coated with anti-human neutrophil apolipoprotein antibody comprises the following steps:
[0022] S1, adding latex particles and a cross-linking surfactant to a cross-linking buffer solution to obtain a latex particle solution;
[0023] S2, dissolving the anti-human neutrophil apolipoprotein antibody in a cross-linking buffer solution to a concentration of 1-1000 μg / mL to obtain an anti-human neutrophil apolipoprotein antibody solution;
[0024] S3, mixing the latex particle solution with the anti-human neutrophil apolipoprotein antibody solution, adding a chemical cross-linking agent and reacting at room temperature for 2-4 hours to obtain latex particles coated with the anti-human neutrophil apolipoprotein antibody.
[0025] In another specific embodiment, the electrolyte is at least one of sodium chloride, potassium chloride, magnesium chloride and magnesium sulfate, and the mass concentration of the electrolyte in the reagent is 0.1-10%.
[0026] In another specific embodiment, the stabilizer is at least one of casein, mannitol, chitosan, disodium ethylenediaminetetraacetic acid, and bovine serum albumin, and the mass concentration of the stabilizer in the reagent is 0.1-10%.
[0027] In another specific embodiment, the buffer is one of MES buffer, borate buffer, acetate buffer, phosphate buffer, and glycine buffer, the concentration of the buffer is 10-500mmoL / L, and the pH value of the buffer is 5-9.
[0028] In another specific embodiment, the surfactant is at least one of Tween, fatty alcohol polyethylene glycol ether, and polyoxyethylene phenyl ether, and the mass concentration of the surfactant in the reagent is 0.1-10%.
[0029] In another specific embodiment, the preservative is at least one of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate, and Proclin preservative, and the mass concentration of the preservative in the reagent is 0.1-10%.
[0030] In another specific embodiment, the chemical crosslinking agent is at least one of EDC, N-hydroxysuccinimide, N-hydroxysulfosuccinimide, carboimide, hydrazide, and potassium isocyanate; the crosslinking buffer is one of MES, MOPSO, MOPS, HEPES, and PBS buffer, and the pH value of the crosslinking buffer is 6-9.
[0031] In another specific embodiment, the concentration of neutrophil apolipoprotein in the quality control product is 0.01-1600 ng / mL.
[0032] The present invention also provides a kit for quantitatively determining neutrophil apolipoprotein in serum for use in assisting the diagnosis of bacterial infection and monitoring the efficacy of antibiotics.
[0033] It is understandable that the kit for quantitative determination of neutrophil apolipoprotein in serum provided by the present invention uses latex enhanced immunoturbidimetry to detect neutrophil apolipoprotein in human serum, which has the characteristics of rapidity, accuracy and stability. Its basic principle is to utilize antigen-antibody specific binding to produce immunoprecipitation reaction to cause liquid phase turbidity change, and then detect the concentration of antigen. Within a certain range, the higher the concentration of antigen, the faster the immunoprecipitation reaction, and the greater the change in liquid phase absorbance.
[0034] The above technical solution of the present invention has the following advantages compared with the prior art:
[0035] The kit for quantitatively measuring neutrophil apolipoprotein of the present invention is a device for measuring neutrophil apolipoprotein in serum by latex enhanced immunoturbidimetry, which has the advantages of stability, accuracy, time saving and labor saving, and can be combined with a full-automatic biochemical analyzer to achieve the effect of full-automatic rapid measurement of clinical detection and analysis of samples. Compared with traditional immunoturbidimetric reagents, the detection sensitivity is improved by more than 10 times, and the anti-neutrophil apolipoprotein monoclonal antibody is coupled to the surface of latex particles by a chemical cross-linking method, and the latex particles and the antibody Fc fragment are combined by chemical bonds, thereby improving the binding rate and stability of the antibody, effectively protecting the active area of the antibody and antigen binding, and improving the detection sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying any creative work.
[0037] Figure 1 It is a curve diagram of absorbance difference when the kit for quantitatively determining neutrophil apolipoprotein in serum described in an embodiment of the present invention detects a sample, wherein the x-axis "cycle" represents the reaction time (each point is 18.5 seconds), and the y-axis represents the absorbance value;
[0038] Figure 2 It is a standard curve diagram of the kit for quantitatively determining neutrophil apolipoprotein in serum described in an embodiment of the present invention for testing a neutrophil apolipoprotein standard, wherein the x-axis represents the concentration of neutrophil apolipoprotein (ng / mL) and the y-axis represents the difference in absorbance. DETAILED DESCRIPTION
[0039] The technical solutions in the embodiments will be described clearly and completely below in conjunction with the accompanying drawings in the embodiments of the present invention.
[0040] Example 1 Monoclonal antibody preparation
[0041] a) The company synthesized the prokaryotic expression plasmid pET-28a(+) capable of expressing the above-mentioned antigen polypeptide, and the plasmid was named pET-HNL-1-AG;
[0042] b) The plasmid was transferred into competent E. coli BL21 (DE3) cells, and the cells were screened for kanamycin resistance. Single colonies were picked for PCR identification, and the positive clones were screened out as the engineered bacteria containing the recombinant plasmid pET-HNL-1-AG.
[0043] c) Expression and purification of recombinant antigen protein - Expression and purification of recombinant plasmid pET-HNL-1-AG in E.coli BL21 (DE3): Inoculate a single colony of E.coli BL21 (DE3) containing the recombinant plasmid pET-HNL-1-AG into 5 mL of LB liquid medium containing 50 μg / mL kanamycin, shake and culture at 200 r / min at 37°C for 9-10 hours, add 5 mL of bacterial solution into 500 mL of LB liquid medium containing 50 μg / mL kanamycin, expand and culture at 1:100 for 2 hours until OD600 is about 0.6. Add IPTG with a final concentration of 0.6mmoL / L to the bacterial solution, shake and culture at 16°C overnight. Collect the overnight induced bacteria by centrifugation, resuspend in LysisBuffer, ice bath for 30 minutes, ultrasonically disrupt for 15 minutes, and collect the supernatant by centrifugation. The recombinant protein in the supernatant was purified by Ni-NTA. The impurities were first washed away with an eluent containing 20 mmoL / L imidazole, and then the recombinant protein was eluted with an eluent containing 200 mmoL / L imidazole.
[0044] (2) Animal immunization BALB / C mice immunization
[0045] On the first day, the serum of mice before immunization was collected intravenously as a negative control. 20 μg of the initial immune antigen recombinant protein was mixed with an equal volume of Freund's complete adjuvant to fully emulsify the antigen and adjuvant. The mice were injected subcutaneously at multiple points in the peritoneum. On the 14th day, the amount of booster immunization antigen was 50% of the initial immunization amount, fully emulsified with an equal volume of Freund's incomplete adjuvant, and injected at multiple points in the peritoneum. Blood was collected venously on the 21st day, and the antibody titer was detected by indirect methods. On the 28th day, booster immunization was performed until a satisfactory immune effect was achieved. For shock immunization, an immunization was performed three days before fusion.
[0046] (3) Cell fusion
[0047] Under sterile conditions, the spleen of the immunized mouse was taken, placed in a plate, and the spleen tissue was rinsed with incomplete culture medium. The spleen capsule was peeled off with two tweezers and the spleen tissue was tweezered to make as many cells as possible free into the incomplete culture medium to facilitate the filtration of spleen cells with a stainless steel wire mesh. Before filtering, the mesh was wetted from below, and the cells were filtered into a 50 mL fusion tube. SP2 / 0 cells in good growth state and in the logarithmic growth phase were mixed with spleen cells at a ratio of 1:10.
[0048] Fusion was mediated by PEG with a molecular weight of 1500. After centrifugation, the cells were resuspended in HAT medium and the well plates were plated with the HAT medium containing the cells, 2 drops per well. The wells were cultured in a 37°C, 5% CO2 incubator. On the third day after fusion, the medium was replaced by half of the HAT medium, and on the fifth and seventh days, the medium was replaced by half of the HAT medium. After two weeks, the medium was replaced by HT medium.
[0049] (4) Monoclonal antibody screening
[0050] Observe the growth of hybridoma cells. When the clone grows to 1 / 3-1 / 2 of the bottom area of the well, take the supernatant and detect it by indirect method to screen positive clones. Use limiting dilution method to clone the hybridoma cells in positive wells. After five times, the antibody positive rate of cloned cells is 100%. Further expand the positive clone cells. Hybridoma cells are continuously passaged in vitro for more than 3 months, repeatedly frozen and revived, and the supernatant is collected regularly. The antibodies in the supernatant are determined by the method of screening antibodies until the cell line can stably secrete monoclonal antibodies.
[0051] (5) Monoclonal Antibody Preparation
[0052] Mice aged 12 weeks or older were selected and injected intraperitoneally with liquid paraffin. One week later, monoclonal hybridoma cells with good growth status were collected and injected intraperitoneally with 1×10 6 After 7-10 days, ascites was collected, and equal volumes of ascites were mixed with normal saline, and precipitated using saturated ammonium sulfate precipitation method. After removing the supernatant, the precipitate was resuspended and dissolved with normal saline, and saturated ammonium sulfate was added again to 33%, the supernatant was discarded, and the precipitate was resuspended and dissolved with normal saline, placed in a dialysis bag, dialyzed, and purified by AKTA protein A chromatography column for use.
[0053] Example 2 Standard Preparation
[0054] a) The company synthesized the prokaryotic expression plasmid pET-28a(+) capable of expressing the above-mentioned full-length polypeptide, and the plasmid was named pET-HNL-1;
[0055] b) The plasmid was transferred into competent E. coli BL21 (DE3) cells, and the cells were screened for kanamycin resistance. Single colonies were picked for PCR identification, and the positive clones were selected as the engineered bacteria containing the recombinant plasmid pET-HNL-1.
[0056] c) Expression and purification of recombinant antigen protein - Expression and purification of recombinant plasmid pET-HNL-1 in E.coli BL21 (DE3): Inoculate a single colony of E.coli BL21 (DE3) containing recombinant plasmid pET-HNL-1 into 5 mL of LB liquid medium containing 50 μg / mL kanamycin, shake and culture at 180 r / min at 37°C for 9-10 hours, add 5 mL of bacterial solution into 500 mL of LB liquid medium containing 50 μg / mL kanamycin, expand and culture at 1:100 for 2 hours until OD600 is about 0.6. Add IPTG with a final concentration of 0.6mmoL / L to the bacterial solution, shake and culture at 16°C overnight. Collect the overnight induced bacteria by centrifugation, resuspend in Lysis Buffer, ice bath for 30 minutes, ultrasonically disrupt for 15 minutes, and collect the supernatant by centrifugation. The recombinant protein in the supernatant was purified by Ni-NTA. The impurities were first washed away with an eluent containing 20 mmoL / L imidazole, and then the recombinant protein was eluted with an eluent containing 200 mmoL / L imidazole.
[0057] Example 3 Kit Preparation
[0058] This embodiment provides a kit for quantitatively determining neutrophil apolipoprotein in serum, the kit comprising reagent 1, reagent 2 and a neutrophil apolipoprotein antigen quality control solution.
[0059] Among them, the reagent 1 is composed of the following components in mass percentage: 0.2% electrolyte, 8% stabilizer, 0.15% surfactant, 5% preservative, and the balance is a buffer solution with a concentration of 10mmoL / L, the electrolyte is sodium chloride, the stabilizer is casein, the surfactant is Tween 20, the preservative is sodium azide, and the buffer solution is MED buffer solution, and its pH value is 6.5.
[0060] The reagent 2 is composed of the following components in mass percentage: 4 mg / mL latex particles coated with anti-neutrophil apolipoprotein monoclonal antibody, 0.2% electrolyte, 8% stabilizer, 0.15% surfactant, 5% preservative, and the balance is a buffer solution with a concentration of 10 mmoL / L. The electrolyte is potassium chloride, the stabilizer is mannitol, the surfactant is fatty alcohol polyethylene glycol ether, the preservative is phenol, and the buffer solution is a phosphate buffer solution with a pH value of 6.5.
[0061] In this embodiment, the anti-human neutrophil apolipoprotein monoclonal antibody is coupled to the surface of latex particles by a chemical cross-linking method, which specifically includes the following steps:
[0062] S1. Add cross-linking surfactant SDS (final mass concentration 0.01%) to 100 mg of latex particles in 5 mL of MES buffer (50 mM, pH 6.5) to obtain a latex particle solution, wherein the particle size of the latex particles is 100-500 nm.
[0063] S2. Dissolve the anti-human neutrophil apolipoprotein monoclonal antibody in 5 mL of MES cross-linking buffer solution (50 mM, pH 6.5) to a concentration of 1 μg / mL to obtain an anti-human neutrophil apolipoprotein monoclonal antibody solution.
[0064] S3. Mix the latex particle solution with the anti-human neutrophil apolipoprotein monoclonal antibody solution, add 100 mg of a chemical cross-linking agent 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), and react at room temperature for 2 hours to obtain latex particles coated with the anti-human neutrophil apolipoprotein monoclonal antibody.
[0065] The neutrophil apolipoprotein antigen calibrator solution includes neutrophil apolipoprotein and a stabilizer, the concentration of the neutrophil apolipoprotein is 0 ng / mL, 100 ng / mL, 250 ng / mL, 500 ng / mL, 750 ng / mL, and 1500 ng / mL, and the stabilizer is bovine serum albumin.
[0066] Experimental Example 4 Kit Application
[0067] 1. Preparation of Standards
[0068] Human neutrophil apolipoprotein purified by gene recombination technology was used as the mother solution, and bovine serum albumin was used to gradiently dilute the mother solution to prepare calibration products: S5: 1600ng / mL, S4: 800ng / mL, S3: 400ng / mL, S2: 200ng / mL, S1: 100ng / mL, S0: 0ng / mL. The concentration of the bovine serum albumin was 1-9999μg / mL.
[0069] 2. Preparation of quality control products
[0070] Human neutrophil apolipoprotein purified by gene recombination technology was used as the mother solution, and bovine serum albumin was used to gradient dilute the mother solution to prepare two concentrations of quality control products: C1: 300 ng / mL, C2: 110 ng / mL. The concentration of the bovine serum albumin was 1-9999 ng / mL.
[0071] 3. Preparation of standard curve
[0072] The main wavelength was 570 nm and the secondary wavelength was 800 nm.
[0073] Reagent dosage: Sample 3μL; Reagent 1: 150μL; Reagent 2: 50μL.
[0074] Determination method (two-point endpoint method): 150 μL of reagent 1 is added to 3 μL of sample, reacted at 37°C for 5 minutes, then 50 μL of reagent 2 is added and kept at 37°C for 30 seconds. The absorbance A1 is measured and the absorbance A2 is measured again after 5 minutes. The absorbance difference ΔA=A2-A1 is calculated. The result is as follows: Figure 1 shown.
[0075] Preparation of standard curve: using the neutrophil apolipoprotein standard of the present invention, the concentrations are S6: 1600ng / mL, S5: 800ng / mL, S4: 400ng / mL, S3: 200ng / mL, S2: 100ng / mL, S1: 50ng / mL, S0: 0ng / mL. According to the above steps, the standard curve of the neutrophil apolipoprotein standard of the present invention is obtained. Figure 2 shown. Figure 2 Each point on the curve represents a standard of content, where the x-axis represents the concentration of neutrophil apolipoprotein and the y-axis represents the difference in absorbance.
[0076] 4. Determination of linear range
[0077] A high-concentration sample of neutrophil apolipoprotein (1600 ng / mL) close to the upper limit of the linear range was diluted with physiological saline at a ratio of 1 / 2, 1 / 4, 1 / 8, 1 / 16, and 1 / 32 to prepare 6 solutions of different concentrations, and physiological saline without neutrophil apolipoprotein was used as a blank solution. Each concentration was detected by the two-point endpoint method, and the measured concentration value and the theoretical concentration were subjected to linear regression analysis. The regression equation was calculated as: y=0.9893x-0.944, and the correlation coefficient r=0.9998, indicating that the kit of the present invention has a good correlation within the linear range of 0 to 1600 ng / mL.
[0078] 5. Accuracy determination
[0079] The kit of the present invention was used to perform serum tests on 20 people using a fully automatic biochemical analyzer (>115.55 ng / mL is a bacterial infection specimen). The test results are shown in Table 1 below, and the results show that the kit of the present invention is highly correlated with clinical symptoms.
[0080] Table 1 Kit accuracy test results
[0081]
[0082] 6. Sensitivity measurement
[0083] Sensitivity is defined as the change in absorbance per unit concentration. The neutrophil apolipoprotein reagent was calibrated on the fully automatic biochemical analyzer using the neutrophil apolipoprotein calibrator, and the absorbance change of the reagent reaction when the calibrator (concentration of 250 ng / mL) was recorded as 0.0687, that is, the sensitivity of the reagent at the calibration concentration of 250 ng / mL was 0.0687.
[0084] 7. Determination of intra-batch precision
[0085] The same sample was measured 10 times using the kit of the present invention, and the measurement mean and intra-batch precision were calculated. The test results are shown in Table 2, and the results show that the intra-batch precision is 0.04%.
[0086] Table 2 Results of intra-batch precision determination of the kit
[0087]
[0088] 8. Anti-interference analysis
[0089] The interference selection formula and test results are shown in Table 3. The results show that the anti-interference ability of the kit of the present invention is good.
[0090] Table 3 Anti-interference analysis results
[0091] Added interfering substances Measured value (ng / mL) Deviation of measured values between the experimental group and the control group Control group: sample + distilled water 51.20 - Test group: sample + triglyceride 51.80 1.10% Test group: sample + bilirubin 51.19 0.50% Test group: sample + hemoglobin 51.62 0.82%
[0092] In summary, the present invention adopts latex enhanced immunoturbidimetry to quantitatively determine neutrophil apolipoprotein, which has the following advantages: 1. Time-saving and labor-saving: antigen-antibody reaction is carried out in a homogeneous reaction system, and the absorbance value of the reaction solution is directly determined by a full-automatic biochemical analyzer, and the result can be obtained in a few minutes, eliminating the tedious operation steps such as repeated incubation and plate washing of the enzyme-linked immunosorbent assay; 2. Stable and accurate: the simplification of the operation steps also correspondingly avoids the interference of many human operation factors and external factors such as reagents and environment, and the stability and repeatability are good, which can more truly reflect the content of neutrophil apolipoprotein in the human serum being tested; 3. Wide application: the sensitivity of the latex enhanced immunoturbidimetry is sufficient to detect the lower limit of neutrophil apolipoprotein, which can fully meet the clinical detection requirements and is significantly better than the immunochromatography (colloidal gold).
[0093] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.
[0094] The above is a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.
Claims
1. A kit for quantitatively determining neutrophil apolipoprotein in human serum, characterized in that: The kit comprises latex particles coated with anti-human neutrophil apolipoprotein antibodies.
2. The kit according to claim 1, characterized in that The anti-human neutrophil apolipoprotein antibody is a monoclonal antibody, which specifically recognizes the antigenic epitope of human neutrophil apolipoprotein. The amino acid sequence of the antigenic epitope is shown in SEQ NO.2: STSDLIPAPPLSKVPLQQC.
3. The kit according to claim 1, characterized in that The latex particles are dissolved in solution 2, and the solution 2 also includes electrolytes, stabilizers, surfactants, preservatives, and buffer solutions.
4. The kit according to claim 3, characterized in that The method for preparing the latex particles coated with anti-human neutrophil apolipoprotein antibody comprises the following steps: S1, adding latex particles and a cross-linking surfactant to a cross-linking buffer solution to obtain a latex particle solution; S2, dissolving the anti-human neutrophil apolipoprotein antibody in a cross-linking buffer solution to a concentration of 1-1000 μg / mL to obtain an anti-human neutrophil apolipoprotein antibody solution; S3, mixing the latex particle solution with the anti-human neutrophil apolipoprotein antibody solution, adding a chemical cross-linking agent and reacting at room temperature for 2-4 hours to obtain latex particles coated with the anti-human neutrophil apolipoprotein antibody.
5. The kit according to claim 1, characterized in that The invention also comprises a solution 1 and a quality control product, wherein the solution 1 comprises electrolytes, a stabilizer, a surfactant, a preservative and a buffer.
6. The kit according to any one of claims 3 to 5, characterized in that The electrolyte is at least one of sodium chloride, potassium chloride, magnesium chloride and magnesium sulfate, and the mass concentration of the electrolyte in the reagent is 0.1-10%.
7. The kit according to any one of claims 3 to 5, characterized in that The stabilizer is at least one of casein, mannitol, chitosan, disodium ethylenediaminetetraacetate and bovine serum albumin, and the mass concentration of the stabilizer in the reagent is 0.1-10%.
8. The kit according to any one of claims 3 to 5, characterized in that The preservative is at least one of sodium azide, phenol, p-hydroxybenzoic acid, ethyl p-hydroxybenzoate and Proclin preservative, and the mass concentration of the preservative in the reagent is 0.1-10%.
9. The kit according to claim 5, characterized in that In the quality control product, the concentration of neutrophil apolipoprotein is 0.01-1600 ng / mL.
10. Use of a kit for quantitatively determining neutrophil apolipoprotein in human serum as claimed in any one of claims 1 to 9 in the preparation of products for diagnosis of bacterial infection and monitoring of antibiotic efficacy.
Citation Information
Patent Citations
Detection kit of latex particle enhanced neutrophil gelatinase-associated lipid transfer protein
CN102253217A
Latex-enhanced immunoturbidimetric assay kit for NGAL, and preparation method thereof
CN107942069A
Kit for determining fecal elastase-1 through latex enhanced immunoturbidimetry
CN110618277A
Assay kit for neutrophil gelatinase-associated lipocalin
WO2018119626A1
